🏆 Winner — CLIC’s Hakim Family Innovation Prize

Introducing

ubiqui Dx

We want you to get tested… wherever you are. An ultra-fast, dual-capacity ultra-sensitive immunoassay and nucleic acid test at the point of care — results in under 5 minutes.

<5 min to result zM sensitivity (10⁻²¹) 6+ log dynamic range Bimodal — immunoassay & nucleic acids

Explore the technology → Talk to the team

McGill University Spinout

The problem

Diagnostic testing is far too inaccessible today.

“

In countries like the United States, where testing can be extremely expensive, governments need to make diagnostics cheaper and more accessible to everyone.

— Bill Gateson pandemic preparedness and health systems

Sensitive, fast and inexpensive diagnostics STILL have not reached the bedside.

The most consequential clinical decisions — in the OR, the ER, the ICU and the doctor’s office — still wait on central labs. ubiqui-Dx sets new standards for accessible diagnostics with decentralized, fast (<5 minutes) and ultra-sensitive point-of-care solutions at a low cost.

⏱️

Turnaround too slow

20 minutes to hours for centralized lab results — even >30 min in a doctor’s office — delaying critical treatment decisions exactly when physicians need them.

💰

Still not decentralized

Most testing is still relegated to central and private labs. Faster, more comprehensive testing needs to reach the doctor’s office, ER, OR and ICU.

ubiqui Dx

The answer

An ultra-fast (<5 minutes), ultra-sensitive immunoassay at the point of care — lab-grade results without the lab.

Executive summary

The company at a glance.

McGill Spinout

Disruptive tech: spinning out the patented Microfluidic Sieve & Detector (MFSD) from Prof. David Juncker’s lab — ultra-sensitive, low-cost immunoassay and molecular tests at the point of care with zeptomolar sensitivity (1000× better than ELISA) and results in <5 minutes.

Four Founders

Paul Chapman (30 yrs — Roche / Merck/Millipore / Quanterix / Domus), Prof. David Juncker (McGill Chair, Canada Research Chair, MFSD platform inventor), Guido Baechler (former CEO Singulex, 20 yrs Roche) and Geunyong Kim (MFSD co-inventor, PhD in Juncker’s lab).

Two Revenue Streams

LDT clinical labs for pre-IVD income, technology validation and licensing → a CLIA-waived point-of-care IVD platform.

Clinical Markets

Beachhead: intraoperative PTH monitoring. Expansion into hs-Troponin (AMI/EMS), Concussion/TBI (GFAP+NfL), Alzheimer’s (pTau217), early cancer detection, microbiology (C. diff), neonatal & adult sepsis — and more.

Why sensitivity matters

The lower the detection limit, the earlier the diagnosis.

Read top to bottom: as concentration falls, the test must get more sensitive. Below the ELISA and Simoa floors, standard tests read “normal” even when disease is present. Only ubiqui-Dx reaches the bottom.

▼ ELISA floor ≈ 1 nM — below here, standard tests read “normal”

nM10⁻⁹

Sepsis — ICU triage

PCT · Procalcitonin

Each hour of delay adds +7% mortality. No point-of-care test exists today.

✓

ELISA

✓

Simoa

✓

ubiqui

pM10⁻¹²

Cardiology — AMI

hs-Troponin

ELISA misses early MI; a 2-hour delay adds +30% mortality.

ELISA

✓

Simoa

✓

ubiqui

▼ Simoa floor ≈ 1 pM — below here, even core-lab analyzers read “normal”

fM10⁻¹⁵

Neurology — TBI

GFAP / NfL

Sideline GFAP is undetectable by ELISA — a second-impact risk.

ELISA

✓

Simoa

✓

ubiqui

aM10⁻¹⁸

Neurology — Alzheimer’s

pTau-217

A 10-year pre-symptom window — needs femtomolar sensitivity to see it.

ELISA

Simoa

✓

ubiqui

zM10⁻²¹

Oncology — PSA · HER2

Early cancer

Stage I: >90% 5-year survival vs. Stage IV: 15%. Earlier detection saves lives.

ELISA

Simoa

✓

ubiqui

Detectable Below detection limit — reads “normal” even when disease is present

Sources: ESC 2020 hs-Troponin Algorithm · JAMA Network Open 2024 (GFAP/TBI) · Chest 2020 (PCT/Sepsis) · Lancet Neurology 2021 (pTau-217) · NEJM Evidence 2023 (PSA) · Walt Lab / Wyss Institute (Simoa)

Sensitivity × speed

MFSD sets the standard for “sensitivity × speed” — for both IA and molecular.

Plotting total assay time against limit of detection, the MFSD test reaches the fast, ultra-sensitive top-right corner that no other immunoassay or molecular method occupies.

Scatter plot of total assay time (2 min to 8 h) versus limit of detection (nM to zM). Rapid tests (LFA), ELISA and bead-based analogue/digital assays cluster at lower sensitivity or slower times; PCR, CRISPR and isothermal amplification trade speed for sensitivity; the MFSD test reaches the fast and ultra-sensitive top-right region.

Faster, more precise decisions

Speed and sensitivity together enable faster and more precise medical decisions.

Lower healthcare costs

If decisions can be made at the bedside or in the doctor’s office, the improvements to testing workflows can decrease overall healthcare costs.

The technology · MFSD

Microfluidic Sieve & Detector.

Patented · McGill University · Prof. David Juncker Lab. A simple polymer membrane with half a million 8-µm pores acts as an array of Brownian affinity traps — sieving 200 µL in about a minute, then detecting single molecules.

MFSD assay workflow: (1) Sieve — a 200 uL sample with protein or nucleic-acid analyte is captured in the Brownian Affinity Trap (~1 min); (2) Detect — captured analyte is oil-capped in the microwells and imaged (~4 min); (3) Analyze — a 5-minute test calibration curve showing zM-aM-fM ultrahigh sensitivity, <=15% CV and 7 orders of magnitude dynamic range.

Limit of detection: 10⁻²¹ M (zeptomolar) | Dynamic range: 6+ orders of magnitude

Feature	ELISA (Lab)	Quanterix (Core Lab)	ubiqui-Dx (POC)
Sensitivity	~pg/mL	~fg/mL	zM (10⁻²¹)
Dynamic range	~2 logs	~3.5 logs	6+ logs
Time to result	4–6 hrs	1–2 hrs	<5 min
Setting	Central Lab	Core Lab	POC / Home
Molecular	N/A	N/A	Yes (bimodal)

📄

Peer-reviewed science

Microfluidic sieve and detector for rapid ultrasensitive assays with single-molecule sensitivity

Kim, Shen, Ng & Juncker — Biomedical Engineering, McGill University (2026)

Read the paper · doi.org/10.1101/2025.10.30.685461 →

Validated performance

Setting the standard for sensitivity × speed.

Benchmarked against ultrasensitive digital immunoassays and PCR — extending both the lower and upper limits of detection.

~50×

Faster IL-4 detection

~350× more sensitive with a 7-order-of-magnitude dynamic range, taking immunoassay from 3–4 hours down to 5 minutes.

vs. ultrasensitive digital immunoassay

~25×

Faster than PCR

For nucleic-acid detection (miR-141): PCR-class sensitivity, but faster, isothermal and far simpler — up to ~10× more sensitive simply by increasing volume.

target: miR-141 · PCR LOD 2 fM

7 OM

Dynamic range

Sensitivity scales linearly with sample volume — from 1,250 to 150,000 positive traps as volume increases at 80 aM analyte.

linear across 7 orders of magnitude

Market opportunity

From a focused entry to global disruption.

io-PTH is only the beginning for an ultra-fast, ultra-low-cost, ultrasensitive platform built on four pillars: low cost, easy to use, very fast and ultrasensitive.

★ LEAD ASSAY

io-PTH

Intraoperative Parathyroid Hormone

Global TAM$200M–$500M

Global SAM$40M–$100M

~200–250K parathyroidectomies / yr globally
8–12% CAGR

❤️

Cardiology

hs-Troponin (AMI/ACS)

TAM$4.2B → $8.8B

SAM$500M–$1.2B

CAGR 10.3%

🧠

Neurology

GFAP · NfL · pTau217

TAM$9.1B → $18.8B

SAM$800M–$2.0B

CAGR 12.9%

🎗️

Oncology

PSA · CEA · AFP · Multi-cancer

TAM$24.5B → $42B

SAM$1.5B–$4.0B

CAGR 11.3%

🦠

C. difficile

Stool Toxin A+B (CDI)

TAM$1.7B → $3.3B

SAM$200M–$600M

CAGR 7.2%

🩸

Sepsis

CRP · PCT · IL-6 · 16S rRNA

TAM$1.1B → $2.7B

SAM$150M–$500M

CAGR 8.1%

References: Coherent Market Insights 2025 · DataIntelo 2024 · Grand View Research 2024–25 · GrowthMarket Reports 2024 · MRFR 2024 · MarketsAndMarkets 2024. SAM = 10–20% TAM penetration estimate (POC-accessible procedures in academic + community hospital settings).

Focused IVD entry

Intraoperative PTH monitoring.

Real-time, whole-blood, sub-pg/mL quantitative io-PTH at the OR table in under 5 minutes — eliminating OR dead-time and reducing the chance of re-operation.

<5 min

Time to result

at the OR table, whole blood

45–90 min

OR dead-time eliminated

≈ $2,700–$13,500 of waiting avoided

$129–$551

Current per-test cost

we expect to be much lower

Four-year roadmap

A phased path to a disruptive POC platform.

Development is synergistic across chemistry, engineering and manufacturing — leveraging AI to optimize R&D, manufacturing and strategic decisions.

2026

2027

2028

2029

2030

Phase 1

Build proof-of-concept for the instrumented solution and pre-clinical validation. ~24 months to POC and pre-clinical validation; clinical validation starts in year one.

Phase 2

Complete prototyping and clinical trials. 12–16 months to clinical-trial readiness, then 6–12 months of clinical trials toward MFSD POC FDA 510(k) submission, CLIA-waived.

Phase 3

Global scaling. Source and scale manufacturing toward full automation; scale commercial operations and manufacturing worldwide.

▸ Leveraging AI for antibody & oligo development, manufacturing and strategy.

▸ Clinical validation begins in year one of the program.

The people

Founders & expert advisors.

Paul Chapman

Co-Founder & CEO

Global operator with 30+ years from sales to CEO across Roche, Merck/Millipore, Quanterix and Domus.

David Juncker

Scientific Co-Founder & CSO

Leading McGill scientist, co-founder of NOMIC Bio, with 15+ inventions and patents in microfluidics and assays.

Geunyong Kim

Scientific Co-Founder

PhD in Juncker’s lab and co-inventor of the BATS / MFSD technology at the core of the platform.

Guido Baechler

Co-Founder & Director

30-year operator and executive; former CEO of Singulex and Mainz BioMed, with 20 years at Roche.

Expert advisors

David C. Duffy, PhD

Technology & Product Advisor

Former CTO & SVP R&D at Quanterix; former VP Research & Operations at Twin Lights Bioscience.

Mark Miller, MD, FRCP(C)

Strategic Advisor — Medical Affairs & Market Access

Former EVP & Chief Medical Officer at bioMérieux; former Full Professor of Medicine at McGill University.

Antti Virtanen

Ultra-Sensitive IA Development

Former Staff Scientist, R&D Strategic Initiatives across Abbott’s Rapid Diagnostics and Point-of-Care divisions.

ubiqui Dx

Diagnostic testing is far too inaccessible today.

Sensitive, fast and inexpensive diagnostics STILL have not reached the bedside.

Turnaround too slow

Still not decentralized

The answer

The company at a glance.

The lower the detection limit, the earlier the diagnosis.

PCT · Procalcitonin

hs-Troponin

GFAP / NfL

pTau-217

Early cancer

MFSD sets the standard for “sensitivity × speed” — for both IA and molecular.

Faster, more precise decisions

Lower healthcare costs

Microfluidic Sieve & Detector.

Setting the standard for sensitivity × speed.

Faster IL-4 detection

Faster than PCR

Dynamic range

From a focused entry to global disruption.

io-PTH

Cardiology

Neurology

Oncology

C. difficile

Sepsis

Intraoperative PTH monitoring.

A phased path to a disruptive POC platform.

Founders & expert advisors.

Paul Chapman

David Juncker

Geunyong Kim

Guido Baechler

Expert advisors

David C. Duffy, PhD

Mark Miller, MD, FRCP(C)

Antti Virtanen

ubiqui-Dx is building a disruptive GLOBAL point-of-care company anchored in Canada.Let’s connect!

ubiqui-Dx is building a disruptive GLOBAL point-of-care company anchored in Canada.
Let’s connect!